(PDF) P2.13-12 the deNovo T790M Mutation Recovered by ddPCR

P2.13-12 the deNovo T790M Mutation Recovered by ddPCR Is Associated With a Poor Response to 1st and 2nd Generation EGFR-TKI in Lung Adenocarcinoma.

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1407

Full Text

Open PDF

Abstract

Available in full text

Date

October 1, 2018

Authors

E.Y. Kim

A. Kim

Y.S. Chang

Publisher

Elsevier BV

Related search

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Journal of Thoracic Oncology

English

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

English

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib

English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics

Cancer Research

Oncology

2016

English

EGFR T790M Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Lung Adenocarcinoma Patients With Acquired Resistance to First Generation EGFR Tyrosine Kinase Inhibitors

English

P3.13-12 a Lung Adenocarcinoma With Concomitant EGFR and De Novo MET Amplification Response Well to Combination of TKI and Bevacizumab

Journal of Thoracic Oncology

English

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

The EGFR T790M Mutation Is Acquired Through AICDA-mediated Deamination of 5-Methylcytosine Following TKI Treatment in Lung Cancer.

Cancer Research

Oncology

2018

English

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

English

Amanote Research

P2.13-12 the deNovo T790M Mutation Recovered by ddPCR Is Associated With a Poor Response to 1st and 2nd Generation EGFR-TKI in Lung Adenocarcinoma.

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1407

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

EGFR T790M Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Lung Adenocarcinoma Patients With Acquired Resistance to First Generation EGFR Tyrosine Kinase Inhibitors

P3.13-12 a Lung Adenocarcinoma With Concomitant EGFR and De Novo MET Amplification Response Well to Combination of TKI and Bevacizumab

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

The EGFR T790M Mutation Is Acquired Through AICDA-mediated Deamination of 5-Methylcytosine Following TKI Treatment in Lung Cancer.

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer